-
Junying YuFounder & Chief Scientist
Bachelor of Peking University, Ph.D. from the University of Pennsylvania, Postdoctoral Fellow at the University of Wisconsin-Madison
One of the international pioneers of hiPSC technology: In 2007, together with Professor James Thomson, the "Father of Human Embryonic Stem Cells", as the first and corresponding author, she reported in Science the successful conversion of human skin cells into induced pluripotent stem cells (iPSCs) under in vitro culture conditions (published in the same year as Professor Shinya Yamanaka's team in Cell ). This achievement earned her selection as a TIME Magazine Person of the Year.
Pioneer of non-integrating reprogramming technology: In 2009, Dr. Junying Yu's groundbreaking work was published in Science, achieving the first generation of footprint-free human iPSCs without exogenous gene DNA damage.
Academic to industrial transformation: From 2009 to 2015, she served as Senior Manager of the Advanced R&D Department at Cellular Dynamics International, founded by Professor James Thomson.
Leading China's hiPSC industry development: In 2016, she founded Nuwacell Biotechnologies Co., Ltd. as Chief Scientist, focusing on developing widely accessible iPSC-derived cell therapy products.
-
Ying ZhangFounder & Chief Technology Officer
Bachelor of the University of Science and Technology of China, Ph.D. and Postdoctoral Fellow of Cornell University
A leading expert in hiPSC industrialization: Boasts years of experience in hiPSC industrial translation both domestically and internationally. Previously served as a Senior Scientist at Cellular Dynamics International.
National project leadership: Undertaken key projects under the 13th and 14th Five-Year National Key R&D Programs of MOST, including "Standardized Research on Stem Cell Preparations and Applications" and "Quality Control and Evaluation Technology for Stem Cells and Related Products".
Pipeline development leadership: Founded Nuwacell Biotechnologies Co., Ltd. in 2016 as Chief Technology Officer and Chief Executive Officer. He has developed diverse hiPSC-derived cell drug pipelines (e.g., iMSC, iNK, iDAP, islet cells) and advanced multiple projects into registered clinical trial stages.
-
Jie XuVice President - Public Relations
Dongbei University of Finance & Economics
Mainly responsible for public relations affairs, possessing extensive experience in public affairs management, with solid practical accumulation and resource networks in the development and maintenance of industry associations, media, and public relations.
-
Peng LinChief Financial Officer
Central University of Finance and Economics, EDHEC Business School (France), Johns Hopkins University
Lin is primarily responsible for formulating and executing the company's financial strategies and financing activities. With over a decade of experience in asset management and investment banking across both international and Chinese markets, as well as many years of in-depth experience in the pharmaceutical and biotech sectors. Mr. Lin has held senior roles including Board Secretary and SVP of Operations at several prominent domestic companies. He is recognized for his long-term strategic vision, sharp market analysis, strong negotiation skills, and robust expertise in risk management.
-
Luyan JiaoVice President - New Drug Development
Ph.D. and Postdoctoral , Sun Yat-sen University
Primarily responsible for project initiation and management within the company, with a solid background in medical science, as well as excellent capabilities in strategic planning, project management and risk control.
-
Weiling JiangVice President - Clinical Operations
Gannan Medical University
Primarily responsible for the management of the operations team and the overall coordination of all clinical trial projects. Possessing extensive senior management experience in clinical operations, having held key management positions such as Clinical Operations Director and Deputy General Manager in several pharmaceutical companies. Equipped with excellent strategic planning, resource integration, and implementation capabilities.
-
Yanqiu LiVice President - Medical Director
Fudan University
Primarily responsible for the company's medical affairs, clinical research and development. Possessing extensive interdisciplinary expertise and medical affairs management experience, having held important positions in multinational pharmaceutical companies such as Novartis and Wyeth. Equipped with excellent cross-departmental integration and resource coordination capabilities.

